Table 1.
Participant characteristics at inclusion
| Characteristic | Placebo | Prednisolone | p value | |
|---|---|---|---|---|
| 7.5 mg | 30 mg | |||
| n | 8 | 12 | 12 | |
| Age (years) | 22 ± 3 | 22 ± 2 | 22 ± 3 | 0.740 |
| Weight (kg) | 76.9 ± 8.7 | 74.8 ± 7.2 | 77.0 ± 5.4 | 0.250 |
| Height (cm) | 184 ± 5.6 | 183 ± 7.6 | 186 ± 4 | 0.641 |
| BMI (kg/m2) | 22.7 ± 2.1 | 22.2 ± 1.9 | 22.4 ± 1.2 | 0.906 |
| LBM (%) | 78.6 ± 7.9 | 82.1 ± 3.9 | 80.7 ± 2.5 | 0.731 |
| Fat mass (%) | 16.9 ± 4.7 | 15.9 ± 2.8 | 14.8 ± 3.5 | 0.531 |
| Systolic BP (mmHg) | 118 ± 11 | 125 ± 9 | 127 ± 9 | 0.172 |
| Diastolic BP (mmHg) | 74 ± 14 | 72 ± 14 | 79 ± 13 | 0.392 |
| FPG (mmol/l) | 5.1 ± 0.3 | 5.0 ± 0.2 | 5.0 ± 0.4 | 0.899 |
| 2 h OGTT (mmol/l) | 4.2 ± 0.8 | 4.7 ± 0.9 | 4.2 ± 1.1 | 0.407 |
Data are mean ± SD
Significance was tested by Kruskal–Wallis. No differences were observed between the groups at baseline